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ABSTRACT 
Purpose 
Safe, effective treatments are needed for pediatric patients with chronic myeloid 
leukemia in chronic phase (CML-CP). Dasatinib is approved in adults with CML-CP. A 
phase 1 study determined suitable dosing for children with Philadelphia chromosome–
positive (Ph+) leukemias. 
 
Methods 
CA180-226/NCT00777036 is a phase 2, open-label, non-randomized prospective trial of 
dasatinib-treated patients aged <18 years in three cohorts: (1) imatinib-
resistant/intolerant CML-CP, (2) imatinib-resistant/intolerant CML in accelerated/blast 
phase or Ph+ acute lymphoblastic leukemia (n=17; data not shown), and (3) newly 
diagnosed CML-CP treated with tablets or powder for oral suspension. Major 
cytogenetic response (MCyR) >30% for imatinib-resistant/intolerant patients and 
complete cytogenetic response (CCyR) >55% for newly diagnosed patients were 
considered of clinical interest. 
 
Results 
Of 113 CML-CP patients, 14 (48%) imatinib-resistant/intolerant and 61 (73%) newly 
diagnosed remained on treatment at time of analysis. MCyR >30% was reached by 3 
months in imatinib-resistant/intolerant and CCyR >55% was reached by 6 months in 
newly diagnosed CML-CP. CCyR and major molecular response by 12 months, 
respectively, were 76% and 41% in imatinib-resistant/intolerant and 92% and 52% in 
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newly diagnosed CML-CP. Progression-free survival by 48 months was 78% in imatinib-
resistant/intolerant and 93% for newly diagnosed CML-CP. No dasatinib-related 
pleural/pericardial effusion, pulmonary edema, or pulmonary arterial hypertension (PAH) 
were reported. Bone growth and development adverse events were reported in 4% of 
patients. 
 
Conclusion 
In the largest prospective trial to date in children with CML-CP, we demonstrate that 
dasatinib is a safe, effective treatment for pediatric CML-CP. Target responses to first- 
or second-line dasatinib were met early, and deep molecular responses were observed. 
Safety of dasatinib in pediatric patients was similar to that observed in adults; however, 
no cases of pleural/pericardial effusion or PAH were reported.  
 
  
Submitted 
8 
 
INTRODUCTION 
While chronic myeloid leukemia (CML) accounts for <5% of leukemias and <1% of all 
cancers in patients <20 years of age,1 more aggressive disease characteristics have 
been observed in pediatric/young adult patients with CML compared with older adults, 
including higher median white blood cell counts, proportionally larger spleen size,  
higher peripheral blasts counts, and lower hemoglobin levels.2 However, there are 
conflicting reports about the prognostic relevance of these variables on outcomes in 
children.3-5 
A need exists for safe and effective treatment options for pediatric CML. The 
BCR-ABL1-target tyrosine kinase inhibitor (TKI) imatinib is the only TKI approved to 
date for frontline treatment of pediatric patients with CML in chronic phase (CML-CP)6; 
however, 25% to 29% discontinue due to poor response or toxicity.7,8 Additionally, there 
are no approved therapies to treat children with imatinib-resistant/intolerant CML-CP. 
There is also a need for formulations of TKIs for younger patients who are unable to 
swallow tablets.9 The development of safe and effective first- and second-line options is 
therefore critical for the successful treatment of children and adolescents with CML.  
Dasatinib is a second-generation TKI that has proven efficacy and safety in 
adults with treatment-naive CML-CP, CML-CP and CML in accelerated/blast phase 
(CML-AP/BP) resistant/intolerant of prior therapy (including imatinib), and Philadelphia 
chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) resistant/intolerant of 
prior therapy.10-14 Previously, dosing and safety of dasatinib in pediatric patients were 
determined in phase I trials.15,16 Here, we present a phase II prospective trial to further 
evaluate safety and efficacy of dasatinib in pediatric patients with CML-CP. 
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METHODS 
Study design 
Study CA180-226 is an ongoing phase II, open-label, nonrandomized, 
multicenter trial investigating dasatinib in pediatric patients with Ph+ leukemia 
(ClinicalTrials.gov identifier: NCT00777036). Patients aged <18 years (protocol was 
amended 9 months after enrollment started to change inclusion criteria from <21 to <18 
years) were enrolled in three cohorts (Fig 1): (1) patients with CML-CP 
resistant/intolerant of imatinib who received dasatinib tablets 60 mg/m2 once daily (QD), 
(2) patients with CML-AP/BP or Ph+ ALL resistant/intolerant of imatinib who received 
dasatinib tablets 80 mg/m2 QD, and (3) patients with CML-CP newly diagnosed who 
received (a) dasatinib tablets 60 mg/m2 QD or (b) powder for oral suspension (PFOS) 
72 mg/m2 QD for ≥12 months; patients were then allowed to switch to tablets. PFOS 
dose was increased by 20% (to 72 mg/m2) to match the exposure of the 60 mg/m2 tablet 
based on bioavailability data in adults. Detailed inclusion/exclusion criteria are listed in 
the Supplementary Appendix. 
Patients could receive dasatinib until disease progression, unacceptable toxicity, 
or patient/physician preference. Patients who discontinued therapy were followed  
yearly for survival, effects on growth and development, and effects on bone metabolism 
up to 5 years after the last dasatinib dose. The protocol was approved by all  
institutional review boards and ethics committees and national competent authorities at 
participating sites. All patients and/or legal guardians gave written informed consent and 
assent where applicable in accordance with the Declaration of Helsinki and local 
guidelines.  
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Evaluations 
Primary objectives were to determine major cytogenetic response (MCyR) for 
patients with imatinib-resistant/intolerant CML-CP, complete hematologic response 
(CHR) for patients with imatinib-resistant/intolerant CML-AP/BP or Ph+ ALL, and 
complete cytogenetic response (CCyR) for patients with newly diagnosed CML-CP at 
any time. MCyR >30% for imatinib-resistant/intolerant CML-CP, CHR >15% for imatinib-
resistant/intolerant CML-AP/BP or Ph+ ALL, and CCyR >55% for newly diagnosed 
CML-CP were considered of clinical interest and align with historic responses in 
pediatric patients with CML-CP.7,8 Secondary objectives included assessments of safety 
and evaluation of best cytogenetic and hematologic response, time to and duration of 
response, disease-free survival (DFS), progression-free survival (PFS), overall survival 
(OS), complete molecular response (CMR), and major molecular response (MMR). The 
description of BCR-ABL1 mutations at baseline (results of which were not available prior 
to start of study treatment), progression, treatment failure, or end of treatment and the 
exploration of the role of mutations as predictors of response were also secondary 
objectives. Database lock for this analysis was November 2016. Detailed definitions of 
efficacy outcomes, safety assessments, mutational analysis, and statistical 
methodology can be found in the Supplementary Appendix. 
 
 RESULTS 
Patients and treatments 
In total, 145 patients were enrolled between March 2009 and September 2014. 
Of these, 130 were treated across three cohorts (Fig 1): 29 with imatinib-
resistant/intolerant CML-CP, 17 with imatinib-resistant/intolerant CML-AP/BP or Ph+ 
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ALL, and 84 with newly diagnosed CML-CP. Newly diagnosed patients were either 
treated with dasatinib tablets (n=51) or ≥12 months of PFOS (n=33). Given the 
observed poor response of patients with imatinib-resistant/intolerant CML-AP/BP or Ph+ 
ALL (CHR was achieved at any time by one of eight patients with CML-BP and four of 
nine patients with Ph+ ALL), and that single-agent TKIs are now considered sub-
standard of care for this pediatric population, this cohort was closed after 17 patients 
were enrolled. Discussion of these data is not included in this report.  
Baseline characteristics for the cohorts of CML-CP are in Table 1. With ≥24 
months of follow-up, 14 (48%) patients with CML-CP resistant/intolerant to imatinib and 
61 (73%) patients with newly diagnosed CML-CP were still receiving study treatment. 
Reasons for exclusion and discontinuation are in Fig 1. The majority of patients 
received the protocol-recommended daily dose of dasatinib (Table 2). Patients who 
were initiated on PFOS were allowed to switch to tablets after being on PFOS for at 
least 1 year. Of the 33 patients on PFOS, 22 (67%) switched to tablets due to patient 
preference. Greater than 38% of patients required at least one dose interruption, 
primarily because of dosing errors and hematologic toxicity (Table 2). Fewer than 25% 
of patients required dose reductions or escalations. 
Efficacy 
Rates of confirmed CHR (cCHR) achieved at any time on treatment were 93% 
(95% confidence interval [CI], 77.2 to 99.2) and 96% (95% CI, 89.9 to 99.3) for patients 
resistant/intolerant of imatinib or those newly diagnosed, respectively. Median time to 
cCHR was 0.7 months (95% CI, 0.5 to 1.8) for imatinib-resistant/intolerant patients and 
1.2 months (95% CI, 0.9 to 1.4) for newly diagnosed patients. 
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The cumulative rate of MCyR >30% was reached as early as 3 months for 
patients with imatinib-resistant/intolerant CML-CP, and the cumulative rate of CCyR 
>55% was reached as early as 6 months for patients with newly diagnosed CML-CP 
(Fig 2). Rapid responses were illustrated by a median time to MCyR of 3.1 months (95% 
CI, 2.8 to 4.1) for imatinib-resistant/intolerant patients and 3.0 months (95% CI, 2.9 to 
4.3) for newly diagnosed patients, and a median time to CCyR of 3.9 months (95% CI, 
2.6 to 5.6) for patients resistant/ intolerant of imatinib and 5.6 months (95% CI, 5.0 to 
6.0) for newly diagnosed patients. Cumulative cytogenetic response rates increased 
over time through 24 months, the minimum follow-up for this analysis (Fig 2). In both 
cohorts, rates of MCyR rose between 3 and 12 months and were maintained through 24 
months. For patients with CML-CP resistant/intolerant of imatinib, rates of CCyR 
consistently rose. Median durations of cytogenetic responses were not reached by the 
time of analysis. 
Additional assessments were performed to determine the rates of cytogenetic 
responses at any time, excluding patients with MCyR/CCyR or unknown cytogenetic 
status at baseline. The results from these assessments were similar to the results 
calculated using the total number of patients in each cohort (Supplementary Appendix 
Table A1).  
Although not focal study endpoints, the cumulative rates of MMR and CMR were 
also observed to increase over time in all cohorts (Fig 3). By 12 months, MMR was 41% 
and CMR was 7% for imatinib-resistant/intolerant patients, and by 24 months, MMR was 
55% and CMR was 17% (Figs 3A and 3C). MMR and CMR were 52% and 8%, 
respectively, by 12 months and 70% and 21%, respectively, by 24 months for the total 
Submitted 
13 
 
newly diagnosed patient population (Figs 3B and 3D). Cohorts in this study were not 
designed to be comparative; however, response rates appeared to be lower for patients 
on PFOS versus tablets. Median time to MMR was 8.9 months (95% CI, 8.1 to 11.7) for 
newly diagnosed patients and was not calculated for the imatinib-resistant/intolerant 
cohort. 
Median PFS and OS have not been reached in any cohort. Seven of 29 (24%) 
imatinib-resistant/intolerant patients and seven of 84 (8%) newly diagnosed patients 
progressed at the time of analyses (Supplementary Appendix Fig A1). Protocol-defined 
reasons for progression were loss of MCyR (n=3 imatinib-resistant/intolerant; n=4 newly 
diagnosed), loss of CHR (n=2 each), and development of CML-BP (n=2 imatinib-
resistant/intolerant; n=1 newly diagnosed). Estimated 48-month PFS was 78% and 93% 
for patients with CML-CP resistant/intolerant of imatinib and patients with newly 
diagnosed CML-CP, respectively (Supplementary Appendix Fig A1). Similar results 
were observed for DFS (Supplementary Appendix Fig A1). One death was reported: a 
patient with CML-CP resistant/intolerant of imatinib died of gastrointestinal bleeding 1 
year after stopping dasatinib. This patient had loss of MCyR prior to death. There were 
no deaths reported for patients with newly diagnosed CML-CP. Estimated 48-month OS 
rate was 96% in the imatinib-resistant/intolerant CML-CP cohort. 
A post hoc analysis of the proportion of patients with BCR-ABL1 ≤10% versus 
>10% at 3 months was performed for the newly diagnosed cohort. Of the 77 patients 
with evaluable transcript levels at 3 months, 60 (78%) had BCR-ABL1 ≤10% and 17 
(22%) had BCR-ABL1 >10%. PFS appeared to be higher for newly diagnosed patients 
with BCR-ABL1 ≤10% versus those with BCR-ABL1 >10% at 3 months (P <.001; 
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hazard ratio 0.10; 95% CI, 0.02 to 0.52); estimated 3-year PFS rates were 
approximately 97% and 82% for patients with BCR-ABL1 ≤10% or >10% at 3 months, 
respectively.  
BCR-ABL1 mutations were assessed at baseline and at the time of disease 
progression, treatment failure, or end of treatment. In the imatinib-resistant/intolerant 
cohort, six of 27 (22%) patients evaluated at baseline had a mutation (E255K, F317L, 
F359V [n=2], V379I, Y253H); five were in cCHR. Of nine patients with assessments at 
end of treatment, three had a mutation (E255K, F317L, T315A). The patients with the 
E255K and F317L mutations had the same mutation at baseline and end of treatment. 
No patient in this cohort had more than one mutation. Mutations in BCR-ABL1 at T315, 
F317, and V299 are now considered resistant to dasatinib17, which was not fully 
understood when this trial began. Of the 78 patients with newly diagnosed CML-CP 
evaluated at baseline, one had a P58S mutation that was found in leukemia cells only. 
This patient was on dasatinib tablets and had cCHR. There were no mutations detected 
in the seven newly diagnosed CML-CP patients evaluated at end of treatment.  
Safety 
The dasatinib-related adverse events (AEs) reported on study are in Table 3. 
There were no occurrences of pleural effusion, pericardial effusion, pulmonary edema, 
pulmonary hypertension, or pulmonary arterial hypertension (PAH) related to dasatinib 
in pediatric patients with CML-CP. In imatinib-resistant/intolerant and newly diagnosed 
patients, any-grade myalgia/arthralgia occurred in 17% and 10%, respectively, and 
fatigue occurred in 14% and 11%, respectively.  
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Dasatinib-related pediatric bone growth and development AEs were grouped 
together for reporting purposes. Grade 1/2 events were reported in five of 113 (4%) 
patients with CML-CP: three of 29 (10%) imatinib-resistant/intolerant patients and two of 
84 (2%) newly diagnosed patients (one in each group). These consisted of epiphyses-
delayed fusion, osteopenia, and gynecomastia (one patient each) in imatinib-
resistant/intolerant patients, and growth retardation (one patient on tablets) and 
gynecomastia (one patient on PFOS) in newly diagnosed patients. Osteopenia and 
gynecomastia in imatinib-resistant/intolerant patients resolved by the time of analysis. 
One dasatinib-related AE occurred more than 30 days after the last dose in a patient 
with imatinib-resistant/intolerant CML-CP (bone density decreased).  
Dasatinib-related serious AEs were reported in five (17%) patients with imatinib-
resistant/intolerant CML-CP and eight (10%) patients with newly diagnosed CML-CP 
(Table 3). No suspected, unexpected serious adverse reactions were reported. There 
was one dasatinib-related AE leading to discontinuation (grade 3 drug hypersensitivity 
which resolved when drug was discontinued). Safety assessment of the 17 pediatric 
patients with CML-AP/BP or Ph+ ALL was consistent with the known safety profile in 
adults with advanced Ph+ leukemias.12-14 
 
DISCUSSION 
CA180-226 is the largest prospective, registrational trial to date in pediatric patients 
diagnosed with CML. With ≥ 24 months of follow-up, high response rates and a 
favorable safety profile for dasatinib were demonstrated in both imatinib-
resistant/intolerant and newly diagnosed patients with CML-CP.  
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This study was designed to explore the most clinically relevant endpoints for 
patients with CML at the time the protocol was developed in 2008: MCyR and CCyR. 
Overall, the efficacy of dasatinib in pediatric patients in this trial was similar to or higher 
than that historically observed in adults. In a phase III dose-optimization trial of adults 
with imatinib-resistant/intolerant CML-CP, 2-year MCyR was 63%18; in pediatric patients 
treated in this study, MCyR rate by 2 years was 90%. Estimated PFS rates at 2 years 
were similar in adults and pediatric patients with CML-CP resistant/intolerant to imatinib 
(80% and 82%, respectively). In adults with newly diagnosed CML-CP from the phase III 
DASISION trial, the cumulative CCyR rate by 2 years was 86%19; the rate in newly 
diagnosed pediatric patients treated here was 94%. Estimated 2-year PFS rates were 
similar in newly diagnosed adults and pediatric patients (94% and 95%, respectively). 
The results described here in patients treated with first-line dasatinib are 
promising compared with results previously reported in pediatric patients treated with 
first-line imatinib. The French National Phase IV Trial (n=44), a prospective study of 
newly diagnosed pediatric patients with CML-CP treated with imatinib 260 mg/m2 daily, 
reported CCyR and MMR rates at 12 months of 61% and 31%, respectively.7 Newly 
diagnosed pediatric patients treated with dasatinib in this study had CCyR and MMR 
rates by 12 months of 92% and 52%, respectively. MMR and CMR are currently 
considered much more relevant objectives of CML therapy, and findings in this trial 
support that deep and durable molecular remissions are achievable at high levels in 
pediatric patients with CML-CP treated with dasatinib. 
Achieving early molecular response (EMR) has been associated with improved 
long-term outcomes in adults and pediatric patients with CML treated with TKIs,20 as 
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well as in pediatric patients with CML treated with imatinib.5 For newly diagnosed 
pediatric patients treated with dasatinib in this study, 78% achieved BCR-ABL1 ≤10% at 
3 months. In the French National Phase IV Trial, 63% achieved this same milestone 
with imatinib.21 This comparison is consistent with results observed in newly diagnosed 
adults treated with dasatinib versus imatinib (84% versus 64% ).22 Such observed 
differences between dasatinib and imatinib may be relevant given the emerging 
evidence that early, deep response is of clinical relevance in CML. In newly diagnosed 
patient populations treated with dasatinib or imatinib, a significant association between 
EMR and PFS was observed.21,22 In contrast, EMR was not correlated with improved 
outcomes in pediatric patients treated with high-dose imatinib.23 
In adults, more patients on dasatinib versus imatinib achieved EMR, shown to 
predict improved long-term survival outcomes, and deep molecular responses, currently 
a requirement for consideration in TKI discontinuation and discontinuation trials.20 Our 
data suggest a possible role for frontline dasatinib in achieving earlier and deeper 
responses in pediatric patients, although long-term studies would be needed to prove 
superiority in survival. Permanent discontinuation of TKIs is a key unmet, and currently 
unstudied, need in the treatment of pediatric CML. Efficacy of dasatinib in imatinib-
resistant/intolerant patients in our study is of particular interest because all but two 
patients were resistant to imatinib. Dasatinib has been shown to be better tolerated than 
imatinib in adults with CML-CP,22 and results described here and in other reports7 
suggest better tolerability of dasatinib compared with imatinib in children with CML. 
Long-term efficacy and safety data from this trial and others, as well as randomized 
trials, are needed to confirm the best frontline TKI for pediatric patients. 
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There were no reported events of pleural effusion or pulmonary hypertension in 
pediatric patients from this trial or from the phase I study.16 In contrast, dasatinib-related 
pleural effusion was reported in 28% of adults with newly diagnosed and imatinib-
resistant/intolerant CML-CP and dasatinib-related pulmonary hypertension was reported 
in 5% of newly diagnosed and 2% of imatinib-resistant/intolerant adults with CML-
CP.22,24 It is possible that the pediatric patients in this study had fewer or no 
comorbidities of cardio-pulmonary nature that would predispose them to the events 
seen in adults.  
Additionally, effects of dasatinib on growth and development were investigated in 
pediatric patients. In a long-term study (median follow-up of 52 months) of pediatric 
patients aged <18 years and treated with high-dose imatinib (340 mg/m2 daily), 22% 
experienced longitudinal growth impairment and/or reduction of bone mineral density.8 
With ≥24 months of follow-up, 4% of children in this study had bone growth and 
development AEs. Follow-up is ongoing to characterize the efficacy and safety of 
chronic dasatinib use, as pediatric patients may live for many decades with CML. Long-
term follow-up is essential considering late toxicities of TKIs have been observed in 
case reports.2,5,25 
A bioequivalence study conducted in adults demonstrated that the bioavailability 
of dasatinib PFOS was 19% lower than that of dasatinib tablets,26 which led to the use 
of 72 mg/m2 dasatinib PFOS in this study. Results reported here were similar between 
tablets and PFOS; however, this trial was not designed to compare cohorts. A 
population pharmacokinetic analysis is ongoing to evaluate dasatinib PFOS exposure in 
pediatric patients. Dasatinib was shown to be safe and well tolerated in pediatric 
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patients at doses up to 120 mg/m2, with no maximum tolerated dose identified in a 
phase I study.16 
This trial was not designed to compare results between cohorts, dasatinib 
treatment in children versus adults, or dasatinib versus imatinib in pediatric patients. 
Similarities and differences described here were based on data from separate trials with 
differences in methodology, patient population, and geographical distribution, which limit 
interpretation. 
Overall, dasatinib treatment produced early, deep, and durable responses of 
clinical importance in this largest prospective trial of pediatric patients with CML-CP to 
date. Target responses were met as early as 3 and 6 months for patients with imatinib-
resistant/intolerant or newly diagnosed CML-CP, respectively. Safety of dasatinib was 
consistent with previous reports in adults, except that no cases of pleural/pericardial 
effusion or PAH were observed in pediatric patients. These results support dasatinib as 
a safe and effective first- or second-line option for the treatment of pediatric CML-CP.  
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Table 1. Baseline Patient Characteristics 
 
Dasatinib-treated patients 
(n=113) 
Imatinib-
resistant/intolerant 
CML-CP 
(n=29) 
Newly diagnosed CML-CP 
Tablets 
(n=51) 
PFOS 
(n=33) 
Total 
(n=84) 
Median age,* 
years (range) 
13.77  
(1.4-20.1) 
12.87  
(1.9-17.8) 
11.70  
(1.8-17.5) 
12.33  
(1.8-17.8) 
Age,* years, n (%) 
<2  1 (3) 1 (2) 1 (3) 2 (2) 
≥2 to <7  3 (10) 5 (10) 5 (15) 10 (12) 
≥7 to <12  6 (21) 16 (31) 12 (36) 28 (33) 
≥12 to <18  17 (59) 29 (57) 15 (45) 44 (52) 
Sex, n (%) 
Male 13 (45) 26 (51) 19 (58) 45 (54) 
Female 16 (55) 25 (49) 14 (42) 39 (46) 
Reason for stopping prior imatinib, n 
Resistance 25 NA NA NA 
Intolerance 2 NA NA NA 
Undetermined† 2 NA NA NA 
Patients with prior therapy,  
n (%) 
Stem cell 
transplant 
1 (3) 0 0 0 
Interferon 4 (14) 1 (2) 0 1 (1) 
Hydroxyurea or 
anagrelide 
14 (48) 23 (45) 10 (30) 33 (39) 
Chemotherapy‡ 3 (10) 0 0 0 
Median time from 
initial CML 
diagnosis to first 
dasatinib dose, 
months (range) 
27.66 (3.0-33.9) 0.69 (0-3.5) 0.46 (0.1-1.4) 0.61 (0-3.5) 
*Two patients with imatinib-resistant/intolerant CML-CP were aged ≥18 years and were 
allowed to continue on study despite not meeting enrolment criteria for age.  
†Investigator reported the protocol eligibility criteria with regard to imatinib resistance 
and/or intolerance were not fully met.  
‡Limited to cytostatic and antineoplastic agents. 
Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; NA, not applicable; 
PFOS, powder for oral suspension.  
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Table 2. Dasatinib Exposure on Study 
 
Dasatinib-treated patients 
(n=113) 
Imatinib-
resistant/intolerant 
CML-CP 
(n=29) 
Newly diagnosed CML-CP 
Tablets 
(n=51) 
PFOS 
(n=33) 
Total 
(n=84) 
Median average daily 
dose, mg/m2 (range) 
58.18  
(35.1-71.7) 
58.54  
(37.2-77.9) 
64.59  
(38.3-98.7) 
59.84  
(37.2-98.7) 
Median duration of 
therapy, months 
(range) 
49.91  
(1.9-90.2) 
52.24  
(7.6-75.2) 
27.40  
(0.1-42.0) 
42.30  
(0.1-75.2) 
Relative dose intensity, n (%) 
50% to <70% 3 (10) 2 (4) 6 (18) 8 (10) 
70% to <90% 4 (14) 13 (25) 11 (33) 24 (29) 
90% to <110% 19 (66) 33 (65) 15 (45) 48 (57) 
≥110% 3 (10) 3 (6) 1 (3) 4 (5) 
Patients with ≥1 dose 
interruption, n (%) 21 (72) 31 (61) 13 (39) 44 (52) 
Dosing error 8 (28) 6 (12) 3 (9) 9 (11) 
Hematologic 
toxicity 5 (17) 13 (25)  6 (18) 19 (23) 
Nonhematologic 
toxicity 6 (21) 9 (18) 4 (12) 13 (15) 
Other 2 (7) 3 (6) 0 3 (4) 
Median duration of 
first interruption, days 
(range) 
8 (2-34) 11 (2-35) 11 (4-19) 11 (2-35) 
Patients with ≥1 dose 
reduction, n (%) 7 (24) 6 (12) 2 (6) 8 (10) 
Dosing error 1 (3) 0 0 0 
Hematologic 
toxicity 3 (10) 4 (8) 2 (6) 6 (7) 
Nonhematologic 
toxicity 3 (10) 2 (4) 0 2 (2) 
Patients with ≥1 dose 
escalation, n (%) 7 (24) 9 (18) 5 (15) 14 (17) 
Resistance 4 (14) 7 (14) 3 (9) 10 (12) 
Other 3 (10) 2 (4) 1 (3) 3 (4) 
No change 0 0 1 (3) 1 (1) 
Median follow-up, 
months (range) 
62.4  
(8.0-90.9) 
54.3  
(16.0-76.6) 
32.5  
(5.2-42.4) 
48.4  
(5.2-76.6) 
Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; PFOS, powder for 
oral suspension. 
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Table 3. On-study Dasatinib-related Adverse Events 
Patients with dasatinib-
related AEs, n (%) 
Dasatinib-treated patients 
(n=113) 
Imatinib-
resistant/intolerant 
CML-CP 
(n=29) 
Newly diagnosed CML-CP 
Tablets 
(n=51) 
PFOS 
(n=33) 
Total 
(n=84) 
Any 
grade Grade 3/4 
Any 
grade Grade 3/4 
Any 
grade Grade 3/4 
Any 
grade Grade 3/4 
All AEs 26 (90) 11 (38) 41 (80) 20 (39) 28 (85) 12 (36) 69 (82) 32 (38) 
AEs of special interest         
Nausea/vomiting 9 (31) 0 9 (18) 0 8 (24) 0 17 (20) 0 
Myalgia/arthralgia 5 (17) 1 (3) 3 (6) 0 5 (15) 0 8 (10) 0 
Fatigue 4 (14) 0 3 (6) 0 6 (18) 0 9 (11) 0 
Rash 4 (14) 0 11 (22) 0 5 (15) 0 16 (19) 0 
Diarrhea 4 (14) 0 11 (22) 0 4 (12) 0 15 (18) 0 
Hemorrhage 3 (10) 0 7 (14) 1 (2) 1 (3) 0 8 (10) 1 (1) 
Pediatric bone growth and 
development 3 (10) 0 1 (2) 0 1 (3) 0 2 (2) 0 
Shortness of breath 3 (10) 0 1 (2) 0 1 (3) 0 2 (2) 0 
Superficial edema 1 (3) 0 3 (6) 0 3 (9) 0 6 (7) 0 
Congestive heart 
failure/cardiac dysfunction 1 (3) 0 2 (4) 0 0 0 2 (2) 0 
Generalized edema 0 0 2 (4) 0 0 0 2 (2) 0 
Cardiac disorders 0 0 1 (2) 0 0 0 1 (1) 0 
Chest pain 0 0 0 0 1 (3) 0 1 (1) 0 
SAEs* 5 (17) 5 (17) 6 (12) 5 (10) 2 (6) 1 (3) 8 (10) 6 (7) 
Neutropenia 2 (7) 2 (7) — — — — — — 
Anemia 1 (3) 1 (3) — — — — 2 (2) 2 (2) 
Left ventricular dysfunction 1 (3) 0 — — — — — — 
Abnormal hepatic function 1 (3) 1 (3) — — — — — — 
Infection 1 (3) 1 (3) — — — — — — 
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Overdose 1 (3) 0 — — — — 1 (1)† 0 
Febrile neutropenia — — — — — — 1 (1) 1 (1) 
Hematochezia — — — — — — 1 (1) 1 (1) 
Peripheral edema — — — — — — 1 (1) 0 
Drug hypersensitivity — — — — — — 1 (1) 1 (1) 
Periorbital cellulitis — — — — — — 1 (1) 1 (1) 
Decreased white blood 
cell count 
— — — — — — 1 (1) 0 
Recurrent leukemia — — — — — — 1 (1) 0 
Uterine hemorrhage — — — — — — 1 (1) 0 
AEs leading to 
discontinuation 0 0 0 0 1 (3)
‡ 1 (3)‡ 1 (1)‡ 1 (1)‡ 
*Patients may have had more than 1 SAE.  
†Grade unknown. 
‡Drug hypersensitivity. 
Abbreviations: AE, adverse event; CML-CP, chronic myeloid leukemia in chronic phase; PFOS, powder for oral 
suspension; SAE, serious adverse event. 
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Figure Legends 
 
Fig 1. CONSORT diagram of study CA180-226. Maximum clinical benefit was defined 
as the achievement of a sufficient remission to proceed to transplant. (*) Patients had 
the option to switch to dasatinib tablets 60 mg/m2 QD following 1 year on PFOS. (†) 
Other includes bone marrow transplant, allogenic bone marrow graft, suboptimal 
response, patient lost to follow-up. (‡) Other includes T315I mutation, loss of major 
molecular response/investigator decision, loss of complete cytogenetic response (n=2), 
hematopoietic stem cell transplant (n=2). (§) Other includes hematopoietic stem cell 
transplant (n=2), suboptimal response, second malignancy, transition to adult hospital 
(n=2). (ǁ) Other includes transfer to adult hospital and bone marrow transplant. CML-
AP/BP, chronic myeloid leukemia in accelerated/blast phase; CML-CP, chronic myeloid 
leukemia in chronic phase; Ph+ ALL, Philadelphia chromosome-positive acute 
lymphoblastic leukemia; QD, once daily. 
 
Fig 2. Cytogenetic responses over time for all treated patients. (A) Cumulative rates of 
major cytogenetic response (MCyR), (B) cumulative rates of complete cytogenetic 
response (CCyR), and (C) median time to and duration of responses. (*) For patients 
who had a best response of CCyR or MCyR. CI, confidence interval; CML-CP, chronic 
myeloid leukemia in chronic phase; PFOS, powder for oral suspension; NE, not 
estimable, median not reached. 
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Fig 3. Cumulative rates of molecular responses over time for all treated patients. Major 
molecular response (MMR) for (A) patients with CML-CP resistant/intolerant of imatinib 
and (B) patients with newly diagnosed CML-CP. Complete molecular response (CMR) 
for (C) patients with CML-CP resistant/intolerant of imatinib and (D) patients with newly 
diagnosed CML-CP. Cohorts were not designed to be comparative. There are numerical 
differences between MMR and CMR in newly diagnosed patients with CML-CP treated 
with dasatinib tablets or PFOS, but CIs overlap. CI, confidence interval; CML-CP, 
chronic myeloid leukemia in chronic phase; PFOS, powder for oral suspension. 
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Fig 1 
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Fig 2 
 
 
C. 
 
Dasatinib-treated patients 
(n=113) 
Imatinib-
resistant/intolerant 
CML-CP 
(n=29) 
Newly diagnosed CML-CP 
Tablets 
(n=51) 
PFOS 
(n=33) 
Total 
(n=84) 
Median time to response,* 
months (95% CI)     
MCyR 3.1 (2.8-4.1) 3.3 (2.9-5.6) 3.0 (2.8-5.0) 3.0 (2.9-4.3) 
CCyR 3.9 (2.8-5.6) 5.7 (3.7-6.2) 5.6 (3.1-6.0) 5.6 (5.0-6.0) 
Median duration of response,* 
months (95% CI)     
MCyR NE (54.9-NE) NE (52.7-NE) NE (NE-NE) NE (52.7-NE) 
CCyR NE (54.9-NE) NE (49.9-NE) NE (NE-NE) NE (49.9-NE) 
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Fig 3 
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SUPPLEMENTARY APPENDIX 
Study Investigators 
The following investigators participated in the study: Argentina – L. A. Aversa 
(Buenos Aires), A. Barretta (Cordoba), A. O. Picon (El Palomar); Australia – C. Fraser 
(South Brisbane), G. McCowage (Westmead), F. Mechinaud (Parkville), M. Osborn 
(North Adelaide), D. Ziegler (Randwick); Brazil – A. L. Brunetto (Porto Alegre), C. A. De 
Souza (Campinas), M. L. de M. Lee (São Paulo), R. Pasquini (Curitiba), M. A. Zanichelli 
(São Paulo); Canada – S. Baruchel (Toronto), M. L. Bernstein (Halifax), S. Desai 
(Edmonton), D. Johnston (Ottawa), A. Narendran (Calgary), Y. Samson (Montreal), K. 
Schultz (Vancouver); France – A. Baruchel (Paris), Y. Bertrand (Lyon), J. Landman-
Parker (Paris), G. Michel (Marseille), F. Millot (Poitiers), F. Rialland (Nantes); Germany 
– T. Lehrnbecher (Frankfurt), D. Reinhardt (Hannover), M. G. Sauer (Hannover); India – 
V. Mathews (Vellore), A. Mukhopadhyay (Kolkatta), G. Narayanan (Trivandrum), S. Patil 
(Bangalore), V. Ramanan (Pune), K. Rathnam (Madurai), T. Saikia (Mumbai), D. H. 
Trivedi (Nayrangpura); Mexico – R. Cadenas Cardos (Ciudad de Mexico), D. Gomez 
Almaguer (Monterrey), G. Gonzalez Villareal (Monterrey), J. J. Kassack Ipina (Ciudad 
de Mexico), A. Medina Sanson (Ciudad de Mexico), F. Sanchez Zubieta (Guadalajara); 
Italy – F. Fagioli (Torino), R. Foa (Roma), F. Locatelli (Pavia), A. Pession (Bologna), C. 
Rizzari (Monza); Netherlands – C. M. Zwaan (Rotterdam); Republic of Korea – N.-G. 
Chung (Seoul), J. J. Seo (Seoul); Romania – A. Colita (Bucharest), M. Dragomir 
(Bucharest), A. Isac (Timisoara); Russian Federation – B. Afanasyev (St. Petersburg), 
A. Maschan (Moscow), S. Mayakova (Moscow); Singapore – E. J. A. Yeoh; Spain – M. 
S. Brunet (Barcelona), V. Castel (Valencia), C. Diaz Heredia (Barcelona), P. Garcia-
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Miguel (Madrid), A. Jimenez-Velasco (Malaga), L. Madero (Madrid), L. Moreno (Madrid); 
South Africa – A. Davidson (Cape Town), D. Reynders (Pretoria), D. C. Stefan 
(Tygerberg), D. K. Stones (Bloemfontein); United Kingdom – J. De La Fuente 
(London), B. Gibson (Glasgow), P. Kearns (Birmingham), D. Lancaster (Sutton); United 
States – R. Aplenc (Philadelphia, PA), J. L. Boklan (Phoenix, AZ), T. M. Cooper 
(Atlanta, GA), B. Degar (Boston, MA), J. Finklestein (Long Beach, CA), L. Gore (Aurora, 
CO), L. Granowetter (New York, NY), N. Hijiya (Chicago, IL), I. Kirov (Orange, CA), M. 
G. Pauly (Atlanta, GA), A. E. Place (Boston, MA), K. R. Rabin (Houston, TX), E. A. 
Raetz (New York, NY), A.K. Ritchey (Pittsburgh, PA), M. Rytting (Houston, TX), N. 
Shukla (New York, NY), L. Stork (Portland, OR), A. Termuhlen (Long Beach, CA), B. 
Thomson (Seattle, WA). 
Methods 
Patients with chronic myeloid leukemia in chronic phase (CML-CP) must have 
had <15% blasts in peripheral blood and bone marrow, <20% basophils in peripheral 
blood, <30% blasts + promyelocytes in peripheral blood and bone marrow, ≥100 × 109 
platelets/L unless thrombocytopenia secondary to recent treatment, no extramedullary 
involvement other than liver and/or spleen, and Philadelphia chromosome-positive 
(Ph+) (with 9;22 translocation) demonstrated by bone marrow cytogenetics. Patients 
with CML in accelerated phase (CML-AP) must have had either ≥15% but <30% blasts 
in peripheral blood or bone marrow, ≥30% blasts + promyelocytes in peripheral blood 
and in bone marrow (but percent alone has to be <30%), ≥20% basophils in peripheral 
blood or bone marrow, or <100 × 109/L platelets unrelated to therapy. Patients with CML 
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in blast phase (CML-BP) must have had either ≥30% blasts in peripheral blood or bone 
marrow or presence of extramedullary disease other than lymph nodes, liver, or spleen.  
Imatinib resistance was defined for patients with CML-CP as either failure to 
achieve or loss of complete hematologic response (CHR) after ≥3 months, failure to 
achieve major cytogenetic response (MCyR) after ≥6 months, failure to achieve 
complete cytogenetic response (CCyR) after ≥12 months, or absolute increase of ≥30% 
of the percentage of Ph+ metaphases after prior MCyR.1 For patients with CML-AP/BP 
or Ph+ acute lymphoblastic leukemia (ALL), imatinib resistance was defined as failure to 
achieve CHR after ≥4 weeks or ≥50% increase in peripheral blood blasts over a 2-week 
period, no longer meeting the criteria for CHR consistently over a consecutive 2-week 
period following the previous achievement of CHR, absolute increase of ≥30% of the 
percentage of Ph+ metaphases after prior MCyR, or (for patients with Ph+ ALL) first or 
subsequent relapse (≥25% bone marrow blasts) or failure to achieve remission.1 
Intolerance of imatinib was defined as the occurrence of any adverse event (AE) grade 
≥3 considered at least possibly related to imatinib that led to discontinuation.  
Women who were pregnant or breastfeeding or who were likely to become 
pregnant, patients for whom potentially curative therapy was immediately available, 
patients with symptomatic involvement of the central nervous system, and patients with 
isolated extramedullary disease (<5% blasts in bone marrow) were excluded. Other key 
exclusion criteria included serious uncontrolled medial disorders, prior dasatinib 
therapy, administration of any investigational agent or other anticancer agent within 14 
days prior to treatment start, and prior chemotherapy, immunotherapy, or radiotherapy 
for CML, except for hydroxyurea (specific to newly diagnosed patients).  
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The 60 mg/m2 and 80 mg/m2 tablet doses were confirmed in a phase I dose-
escalation study.2 Based on the findings from a bioequivalence study in adults where 
the bioavailability of powder for oral suspension (PFOS) was 19% lower than the tablet,3 
the selected PFOS dose was increased by 20% (to 72 mg/m2) to match the exposure of 
the 60 mg/m2 tablet in order to maintain a desired efficacy.  
CHR must have been confirmed at least 4 weeks after the first documentation. 
For patients with CML-CP, CHR was defined as white blood cell count <10,000/mm3, 
platelet count <450,000/mm3, peripheral blood basophils <5%, no blasts or 
promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral 
blood, and no extramedullary involvement (including no splenomegaly or 
hepatomegaly). For patients with CML-AP/BP or Ph+ ALL, CHR was defined as <5% 
blasts in bone marrow aspirate, white blood cell count less than or equal to the upper 
limit of normal with no immature cells (ie, blasts, promyelocytes, myelocytes, 
metamyelocytes) in peripheral blood, absolute neutrophil count ≥1,000/mm3, platelet 
count ≥100,000/mm3 and ≤450,000/mm3, and no evidence of extramedullary leukemia 
including no hepatomegaly or splenomegaly, but excluding isolated leptomeningeal 
leukemia. Cytogenetic responses were based on the percentage of Ph+ metaphases 
among ≥ 20 metaphases in the bone marrow aspirate as follows: CCyR=0% and 
MCyR=0% to 35%.  
Molecular responses were assessed using BCR-ABL1 transcript levels in 
peripheral blood measured by real-time quantitative polymerase chain reaction by a 
central laboratory (MolecularMD, Portland, OR). Mutational analyses of peripheral blood 
samples by Sanger sequencing were also conducted by this central lab. Complete 
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molecular response was defined as the ratio BCR-ABL1/ABL1 ≤ 10-4.5 or 0.00316% of 
the International Scale (IS) and major molecular response was defined as the ratio 
BCR-ABL1/ABL1 ≤ 10-3 or 0.1% IS.4,5 Molecular assessment were performed within 2 
weeks prior to first dose of study therapy, and then every 3 months until month 24. 
Following month 24, the molecular assessment was conducted every 6 months until 
disease progression or end of study therapy, whichever occurred first, and at the end of 
treatment visit. Maximum clinical benefit was defined as the achievement of a sufficient 
remission to proceed to transplant. 
Progression was defined based on guidelines available during protocol design6 
as progression to CML-AP/BP (for patients with CML-CP), increasing white blood cell 
count, loss of CHR, loss of MCyR, or death. Patients who did not progress or die were 
censored for PFS on their last cytogenetic or hematologic assessment. Patients who did 
not die or who were lost to follow-up were censored for overall survival on the last day 
they were known to be alive. Disease-free survival was defined as the time from CCyR 
(patients with CML-CP) or CHR (patients with CML-AP/BP or Ph+ ALL) until the time of 
progression or death. 
AEs were reported continuously and graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,7 the 
active grading system at the time of trial initiation. Investigator-reported AE terms were 
coded and grouped by system organ class using the Medical Dictionary for Regulatory 
Affairs (MedDRA) dictionary version 19.0.8 Serious AEs were defined as events 
resulting in death, that were life-threatening, requiring inpatient hospitalization or 
prolonging existing hospitalization, resulting in persistent or significant 
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disability/incapacity, a congenital anomaly/birth defect, or an important medical event 
(based on appropriate medical and scientific judgment). Suspected, unexpected serious 
adverse reactions were termed by the European Clinical Trial Directive 2001/20/EC.9 
A single dose escalation to 80 mg/m2 was allowed for patients who did not 
achieve an acceptable response and were tolerating therapy; AEs were managed 
through dose interruptions and reductions (to 50 mg/m2, then 40 mg/m2). Relative dose 
intensity is the average daily dose divided by the planned starting dose. The average 
daily dose is the cumulative dose administered across the treatment period divided by 
the length of the treatment period. The length of the treatment period is from day 1 of 
dasatinib treatment through the last day of dasatinib treatment. For a patient continuing 
treatment, the last day of dasatinib treatment is the last known day of dasatinib 
treatment by the time the database was locked. 
The study was designed to enroll and treat at least 25 patients with imatinib-
resistant/intolerant CML-CP, 34 patients with CML-AP/BP or Ph+ ALL, 50 patients with 
newly diagnosed CML-CP on tablets, and 30 patients with newly diagnosed CML-CP on 
PFOS. The following statements are based on using a one-sided type I error rate of 
2.5%. Assuming a 60% MCyR rate among patients with imatinib-resistant/intolerant 
CML-CP (30% more than the response rate under the null hypothesis), a sample size of 
25 patients would yield 84% power to rule out a 30% response rate. Assuming a 35% 
CHR rate among patients with CML-AP/BP or Ph+ ALL (20% more than the response 
rate under the null hypothesis), the planned sample size of 34 patients would yield 80% 
power to rule out a 15% response rate. However, given that enrollment in this cohort 
was closed early, analyses with respect to that cohort can only be based on the 17 
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treated subjects and drug would be considered of clinical interest if there were at least 
seven responders out of the total of 17 response-evaluable patients. Assuming a 75% 
CCyR rate among patients with newly diagnosed CP-CML (20% more than the 
response rate under the null hypothesis), a sample size of 50 subjects would yield 83% 
power to rule out a 55% response rate. The proposed pharmacokinetic (PK) sampling 
design in the 30 patients on PFOS provides an adequate estimate of PK parameters, 
such that the 95% confidence interval (CI) of clearance and volume of distribution are 
within 60% and 140% of the geometric mean estimate across pediatric subgroups (body 
weight 10 to 100 kg).  
Long-term growth and development and bone metabolism assessments include 
bone age, Tanner stage, hormone levels (T4, thyroid-stimulating hormone, follicle-
stimulating hormone [for children >8 years old], luteinizing hormone [for children >8 
years old]), growth factor levels (insulin-like growth factor [IGF]-1/IGFB-3), urinary N-
telopeptide levels, bone alkaline phosphatase levels, and dual energy X-ray 
absorptiometry (DeXA) scanning. DeXA scanning includes bone mineral content and 
density measures in lumbar spine, total body (less head), total hips, and femoral neck. 
There was no central review of DeXA results. 
Statistical analyses 
Study cohorts were not designed to be comparative. The exact two-sided 95% 
Clopper-Pearson CI was calculated for response rates. Time-to-event endpoints were 
estimated by the Kaplan-Meier method and two-sided 95% CIs for medians were 
calculated using the method of Brookmeyer and Crowley. The Cox proportional hazards 
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model was used to compute hazard ratios. An exact single-stage design was used to 
test in each cohort whether dasatinib response rates were of clinical interest.  
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Table A1. MCyR or CCyR at Any Time Based on Baseline Cytogenetic Response 
 
 Imatinib-resistant/intolerant CML-CP 
(n=29) 
Newly diagnosed CML-CP (n=84) 
Responses at 
any time, % 
(95% CI) 
Excluding patients 
with MCyR or 
unknown cytogenetic 
status at baseline All treated patients 
Excluding patients 
with CCyR or 
unknown cytogenetic 
status at baseline All treated patients 
MCyR 90.0 (68.3-98.8) 89.7 (72.6-97.8) — — 
CCyR — — 93.9 (86.3-98.0) 94.0 (86.7-98.0) 
Abbreviations: CCyR, complete cytogenetic response; CI, confidence interval; CML-CP, chronic myeloid leukemia in 
chronic phase; MCyR, major cytogenetic response. 
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Figure legend 
 
Fig A1. Kaplan-Meier survival curves for all treated patients. Progression-free survival 
(PFS) for (A) patients with CML-CP resistant/intolerant of imatinib and (B) patients with 
newly diagnosed CML-CP. Disease-free survival (DFS) for (C) patients with CML-CP 
resistant/intolerant of imatinib and (D) patients with newly diagnosed CML-CP. CI, 
confidence interval; CML-CP, chronic myeloid leukemia in chronic phase; PFOS, 
powder for oral suspension. 
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Fig A1
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